SEQUA Stock Overview Develops and commercializes treatments for patients with diuretic-resistant fluid overload in liver disease, cancer, and heart failure in Belgium, Germany, France, Switzerland, and internationally. More details
Rewards Risk Analysis + 2 more risks
See All Risk Checks Capture your thoughts, links and company narrative
Sequana Medical NV Competitors Price History & Performance
Summary of share price highs, lows and changes for Sequana Medical Historical stock prices Current Share Price €0.70 52 Week High €4.85 52 Week Low €0.47 Beta 0.88 1 Month Change -18.84% 3 Month Change -24.30% 1 Year Change -82.19% 3 Year Change -90.39% 5 Year Change -88.89% Change since IPO -91.71%
Recent News & Updates Sequana Medical NV Announces Board Resignations
New major risk - Shareholder dilution Nov 21
First half 2024 earnings: Revenues exceed analysts expectations while EPS lags behind Oct 03
New major risk - Shareholder dilution Aug 23
Sequana Medical Announces Data on Alfapump® Safety and Quality of Life to Be Presented At EASL Congress 2024 Jun 08
Full year 2023 earnings: EPS and revenues miss analyst expectations Apr 24 See more updates Sequana Medical NV Announces Board Resignations
New major risk - Shareholder dilution Nov 21
First half 2024 earnings: Revenues exceed analysts expectations while EPS lags behind Oct 03
New major risk - Shareholder dilution Aug 23
Sequana Medical Announces Data on Alfapump® Safety and Quality of Life to Be Presented At EASL Congress 2024 Jun 08
Full year 2023 earnings: EPS and revenues miss analyst expectations Apr 24
Sequana Medical NV to Report First Half, 2024 Results on Sep 19, 2024 Apr 11
Sequana Medical NV to Report First Half, 2024 Results on Sep 12, 2024 Apr 10
Sequana Medical Announces Strong Data from DSR Proof-of-Concept Studies in Heart Failure Published in European Journal of Heart Failure Apr 05
No longer forecast to breakeven Apr 04
New minor risk - Financial data availability Apr 03 Sequana Medical NV has filed a Follow-on Equity Offering in the amount of €12 million.
Price target decreased by 26% to €7.63 Feb 16 Sequana Medical NV, Annual General Meeting, May 23, 2024
Forecast to breakeven in 2026 Jan 23
New minor risk - Market cap size Jan 18
Sequana Medical NV Announces Positive Data from Non- Randomized Cohort in US Phase 1/2a MOJAVE Study of DSR® 2.0 for Treatment of Heart Failure Nov 29
Sequana Medical NV Appoints Ids Van Der Weij as Non-Executive Director Nov 11
Sequana Medical NV Announces Initial Positive Data from MOJAVE, a US Phase 1/2A Study of DSR 2.0 for Treatment of Heart Failure through Breaking Vicious Cycle of Cardiorenal Syndrome Oct 18
Forecast to breakeven in 2024 Sep 25
First half 2023 earnings released: €0.65 loss per share (vs €0.68 loss in 1H 2022) Sep 17
New major risk - Financial position Sep 15
Sequana Medical NV to Report Q2, 2023 Results on Sep 14, 2023 Aug 28
Sequana Medical NV Announces First Patient Enrolled in Mojave, a US Randomized Controlled Phase 1/2a Study of DSR 2.0 for Treatment of Compostive Heart Failure Jul 12
Forecast to breakeven in 2024 Jul 12
Sequana Medical NV Announces Completion of 1,000th Alfapump Implant Jul 06
Sequana Medical NV Appoints Kenneth Macleod as Non-Executive Director Jun 27
Price target decreased by 22% to €12.50 Jun 21
Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind May 01
Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind Feb 12
Sequana Medical Announces Successful Completion of Pre-Clinical Studies with its Second-Generation DSR Product for Congestive Heart Failure Feb 08
Price target increased to €16.00 Nov 16
Sequana Medical NV Announces Positive Top-Line Results from SAHARA Ph. 2a Study of DSR 1.0 in Diuretic-Resistant Heart Failure Patients with Persistent Congestion and First Patient Dosed Successfully with DSR 2.0 in YUKON Nov 15
High number of new directors Oct 31
Sequana Medical NV Announces Positive Top-Line Results from the North American Pivotal POSEIDON study of the alfapump Oct 25
First half 2022 earnings released: €0.68 loss per share (vs €0.66 loss in 1H 2021) Sep 09 Sequana Medical NV to Report Fiscal Year 2022 Final Results on Apr 25, 2023
Sequana Medical NV Announces Board Changes Aug 25
Price target increased to €13.75 Jul 21
Sequana Medical NV Appoints Doug Kohrs as an Independent Non-Executive Director of the Company Jul 20
Sequana Medical Completes Enrollment in Phase 2a SAHARA I DSR, Reports Disease-Modifying Profile for Short Term DSR Jul 19
Price target decreased to €11.75 Apr 27
High number of new and inexperienced directors Apr 27
Full year 2021 earnings: EPS and revenues miss analyst expectations Apr 13
Sequana Medical Announces the Completion of Alfapump Implantations in Poseidon, the North American Pivotal Alfapump Study Apr 06
Sequana Medical NV Receives Certification Under Mdr, the New European Medical Device Regulation Feb 15 Sequana Medical Announces Positive Interim Results of SAHARA DESERT
First half 2021 earnings released: €0.66 loss per share (vs €0.62 loss in 1H 2020) Sep 04
Independent Non-Executive Director Jason Hannon has left the company Sep 01
Sequana Medical’s Results from RED DESERT Alfapump DSR® Study Presented as One of the Highlights At Heart Failure 2021 Online Congress Jul 07
Full year 2020 earnings released: €1.25 loss per share (vs €1.22 loss in FY 2019) Jul 03
Sequana Medical Announces Positive Results From Second Interim Analysis of North American Pivotal alfapump® Study (POSEIDON) Jul 02
Sequana Medical Announces First Patient Enrolled in SAHARA DESERT Jun 01
Sequana Medical NV Announces Positive Top-Line Results from the Red Desert Study with Repeated Dose Alfapump DSR® (Direct Sodium Removal) Therapy in Diuretic-Resistant Heart Failure Patients May 11
Health Check: How Prudently Does Sequana Medical (EBR:SEQUA) Use Debt? Mar 19
Full year 2020 earnings released: €1.25 loss per share (vs €1.22 loss in FY 2019) Mar 18
Sequana Medical NV, Annual General Meeting, May 27, 2021 Mar 17
Price target lowered to €13.00 Feb 12
Did Sequana Medical's (EBR:SEQUA) Share Price Deserve to Gain 51%? Jan 26
New 90-day high: €7.96 Dec 17
Do Institutions Own Sequana Medical NV (EBR:SEQUA) Shares? Dec 03
Sequana Medical Announces Positive Interim Data from North American Pivotal Alfapump® Study (Poseidon) Nov 19
New 90-day high: €7.00 Nov 19
Sequana Medical NV Announces Scientific Advisors Appointments Oct 15 Sequana Medical NV to Report Fiscal Year 2020 Results on Mar 17, 2021
First half earnings released Sep 05
New 90-day low - €6.02 Aug 27 Shareholder Returns SEQUA BE Medical Equipment BE Market 7D -12.8% -0.5% 0.03% 1Y -82.2% 7.1% 1.6%
See full shareholder returns
Return vs Market: SEQUA underperformed the Belgian Market which returned 1.6% over the past year.
Price Volatility Is SEQUA's price volatile compared to industry and market? SEQUA volatility SEQUA Average Weekly Movement 20.8% Medical Equipment Industry Average Movement 6.2% Market Average Movement 3.6% 10% most volatile stocks in BE Market 6.6% 10% least volatile stocks in BE Market 2.2%
Stable Share Price: SEQUA's share price has been volatile over the past 3 months compared to the Belgian market.
Volatility Over Time: SEQUA's weekly volatility has increased from 15% to 21% over the past year.
About the Company Sequana Medical NV develops and commercializes treatments for patients with diuretic-resistant fluid overload in liver disease, cancer, and heart failure in Belgium, Germany, France, Switzerland, and internationally. The company products pipeline comprises alfapump system, an implantable pump system for the treatment of refractory liver ascites and malignant ascites; and Direct Sodium Removal (DSR) for the treatment of fluid overload spread across the body and heart failure. Sequana Medical NV was founded in 2006 and is headquartered in Gent, Belgium.
Show more Sequana Medical NV Fundamentals Summary How do Sequana Medical's earnings and revenue compare to its market cap? SEQUA fundamental statistics Market cap €32.17m Earnings (TTM ) -€27.18m Revenue (TTM ) €433.50k
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) SEQUA income statement (TTM ) Revenue €433.50k Cost of Revenue €101.74k Gross Profit €331.76k Other Expenses €27.51m Earnings -€27.18m
Last Reported Earnings
Jun 30, 2024
Earnings per share (EPS) -0.61 Gross Margin 76.53% Net Profit Margin -6,269.81% Debt/Equity Ratio -111.3%
How did SEQUA perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/19 19:38 End of Day Share Price 2024/12/19 00:00 Earnings 2024/06/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Sequana Medical NV is covered by 5 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Laura Roba Degroof Petercam Yi Chen H.C. Wainwright & Co. Thomas Vranken KBC Securities NV
Show 2 more analysts 
